(Q28144942)

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Counting events in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Controversy in Counting and Attributing Events in Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

The randomized clinical trial: bias in analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Controversies and achievements in clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Analysis of clinical trials by treatment actually received: is it really an option?

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Intention-to-treat analysis: implications for quantitative and qualitative research

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Intention-to-treat analysis and the goals of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Practical implications of modes of statistical inference for causal effects and the critical role of the assignment mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

A method for the analysis of randomized trials with compliance information: an application to the Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Correcting for non-compliance in randomized trials using rank preserving structural failure time models

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Estimating the causal effect of compliance on binary outcome in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

More powerful randomization-based p-values in double-blind trials with non-compliance.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Explanatory and pragmatic attitudes in therapeutical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Random-effects models for longitudinal data

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Missing data in longitudinal studies

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Intention-to-treat analyses for incomplete repeated measures data.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

A comparison of the random-effects pattern mixture model with last-observation-carried-forward (LOCF) analysis in longitudinal clinical trials with dropouts.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

A multiple imputation strategy for clinical trials with truncation of patient data

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Multiple imputation methods for the missing covariates in generalized estimating equation

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Intent-to-treat analysis for longitudinal studies with drop-outs.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

On a model-based approach to estimating efficacy in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

On estimating efficacy from clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Adjusting for non-compliance and contamination in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Statistical handling of drop‐outs in longitudinal clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Estimation and comparison of changes in the presence of informative right censoring: conditional linear model

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Methods for the analysis of informatively censored longitudinal data

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Testing for differences in changes in the presence of censoring: parametric and non-parametric methods.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Worst-rank score analysis with informatively missing observations in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Introduction to sample size determination and power analysis for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

A graphical assessment of the potential impact of losses to follow-up on the validity of study results. The Terry Beirn Community Programs for Clinical Research on AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

A note on the bias of estimators with missing data.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

Implementation of a multicomponent process to obtain informed consent in the Diabetes Control and Complications Trial. The DCCT Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0197-2456%2800%2900046-5

7 January 2021

10.1016/S0197-2456(00)00046-5

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

10822117

1 reference

Consolidated OpenCitations Corpus – April 2017